Opinion|Videos|November 4, 2024

Neonatal Fc Receptors in Treatment of Generalized Myasthenia Gravis

Key Takeaways

  • FcRn-targeting agents for gMG vary in their mechanisms, primarily by inhibiting FcRn to lower pathogenic IgG levels or modulating immune responses.
  • Both approved and investigational FcRn-targeting drugs possess distinct pharmacological profiles, impacting their therapeutic applications.
SHOW MORE

Panelists discuss how various approved and investigational FcRn-targeting agents differ in their mechanisms of action for treating generalized myasthenia gravis (gMG).

Episodes in this series

Video content above is prompted by the following:

  • A number of agents targeting the neonatal Fc receptor (FcRn) have recently been approved or are under investigation to treat gMG. What are the differences regarding mechanism of action among the following approved or investigational FcRn-targeting agents?

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Subscribe Now!

Related Content

Latest CME

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One
Video

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Estelamari Rodriguez, MD, MPH; Millie Das, MD; Ruham Nasany, MD

View more
Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients
Video

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Anne Chiang, MD, PhD; J. Douglas Miles, MD, PhD, FAAN; Suma Satti, MD

View more
Patient, Provider, and Caregiver Connection: Improving Diagnosis and Care for Adolescent Myasthenia Gravis Patients – A New Frontier
Video

Patient, Provider, and Caregiver Connection: Improving Diagnosis and Care for Adolescent Myasthenia Gravis Patients – A New Frontier

Abigail N. Schwaede, MD; Emmanuelle (Noelle) Tiongson, MD

View more
A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden
Video

A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden

Shamik Bhattacharyya, MD, MS, FAAN; Mirla Avila, MD; Dean Wingerchuk, MD

View more
PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)
Audio

PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

Richard Bedlack, MD, PhD

View more
PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)
Audio

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

Terry Heiman-Patterson, MD

View more